Table 1.
Patients’ baseline characteristics and major outcomes.
| Patient IDa | Diagnosis | Metastasis | Genetic profile | Induction therapy | Response on induction (RECIST v1.1) | Vaccine Dose(s) | Maintenance therapy | ECOG score | KPS | Age at enrollment | Sex | Post vaccine response (RECIST v1.1) | Post vaccine response (irRECIST) | PFS (weeks) | Additional anticancer treatment |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 01–0001A | Adenocarcinoma of the left colon | Liver | KRAS mut, MSS, HER2 pos | FOLFOX + bevacizumab | SD | 1 | 5-FU, leucovorin, bevacizumab | 1 | 90 | 62 | M | PD | NE | 13 | NA |
| 02–0001A | Adenocarcinoma of the hepatic flexure | Synchronous liver | KRAS mut, MSS | FOLFOXIRI + bevacizumab | PR | 1 | 5-FU, leucovorin, bevacizumab | 0 | 100 | 64 | F | PD | irPD | 10 | NA |
| 02–0002A | Adenocarcinoma of the left colon | Synchronous liver | RAS/BRAF wt, HER2 neg, MSS | FOLFOX + panitumumab | SD | 1 | 5-FU, leucovorin, panitumumab | 0 | 100 | 59 | M | SD | NE | 31 | NA |
| 02–0003A | Rectal adenocarcinoma | Synchronous liver and lung | KRAS mut, MSS | FOLFOX + bevacizumab | PR | 1 | 5-FU, leucovorin, bevacizumab | 0 | 100 | 73 | M | SD | NE | 26b | Radiotherapy |
| 02–0004A | Adenocarcinoma of the right colon | Synchronous liver | KRAS mut, MSS | FOLFOXIRI + bevacizumab | PR | 1 | 5-FU, leucovorin, bevacizumab | 1 | 100 | 66 | M | PR | NE | 27 | NA |
| 01–0008B | Rectal adenocarcinoma | Liver | KRAS mut, MSS, HER2 neg | FOLFOX + bevacizumab | SD | 1 | Capecitabine, bevacizumab | 0 | 90 | 48 | M | PD | irPD | 10 | NA |
| 01–0003B | Rectosigmoid adenocarcinoma | Liver and lung | RAS wt, BRAF wt, MSS | FOLFOX + bevacizumab | SD | 2 | 5-FU, leucovorin, bevacizumab | 0 | 90 | 49 | M | SD | NE | 25b | NA |
| 01–0002B | Rectal adenocarcinoma | Liver | KRAS mut, MSS, HER2 neg | FOLFOXIRI + bevacizumab | PR | 3 | 5-FU, leucovorin bevacizumab | 0 | 100 | 54 | M | SD | NE | 54 | NA |
| 01–0004B | Adenocarcinoma of the cecum | Liver and omentum, mesentery | KRAS mut, MSS, HER2 neg | FOLFOX + bevacizumab | SD | 3 | Capecitabine, bevacizumab | 0 | 90 | 45 | M | PR | irPR | 25b | Surgery |
| 01–0005B | Rectosigmoid adenocarcinoma | Liver and peritoneal | KRAS mut, MSS, HER2 neg | FOLFIRI + bevacizumab | SD | 3 | Capecitabine, bevacizumab | 0 | 100 | 37 | M | PD | irPD | 32 | NA |
| 01–0007B | Rectosigmoid adenocarcinoma | Liver, with lymphadenopathy – supraclavicular, axilla, mediastinum, hilum | RAS/BRAF wt, MSS, HER2 neg | FOLFOX + cetuximab | PR | 3 | 5-FU, leucovorin, cetuximab | 0 | 90 | 52 | M | PR | irPR | 56b | Surgery |
Abbreviations: FOLFOX, 5-fluorouracil (Adrucil, Fluorouracile Teva), leucovorin calcium, oxaliplatin (Eloxatin, Oxaliplatino Sun); FOLFOXIRI, 5-fluorouracil (Adrucil, Fluorouracile Teva), leucovorin calcium, oxaliplatin (Eloxatin, Oxaliplatino Sun), irinotecan (Camptosar, Irinto), bevacizumab (Avastin), capecitabine (Xeloda, Capecitabina Accord), panitumumab (Vectibix), cetuximab (Erbitux); KPS, Karnofsky Performance Score; NE, not evaluated.
aSuperscripts in patient ID indicate the study part (A or B).
bCensored data.